Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | SCD | O00767 | 1/20 | 0.30 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.30 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22819130 | 0.86 | GRM5 (0.41) | GRM5ALDH1A1LMNASMN1; SMN2CHRNA1 | |
| SCHEMBL85820 | 0.83 | GRM5 (0.44) | GRM5ALDH1A1LMNASMN1; SMN2CHRNA1 | |
| SCHEMBL22662499 | 0.77 | GRM5 (0.41) | GRM5ALDH1A1LMNASMN1; SMN2CHRNA1 | |
| SCHEMBL11405351 | 0.77 | GRM5 (0.44) | GRM5ALDH1A1LMNASMN1; SMN2CHRNA1 | |
| SCHEMBL19135319 | 0.74 | — | — | |
| SCHEMBL20375480 | 0.74 | — | — | |
| SCHEMBL21345315 | 0.74 | ALDH1A1 (0.41) | GRM5ALDH1A1LMNASMN1; SMN2CHRNA1 | |
| SCHEMBL28297302 | 0.74 | ALDH1A1 (0.41) | GRM5ALDH1A1LMNASMN1; SMN2CHRNA1 | |
| SCHEMBL22911649 | 0.74 | GRM5 (0.39) | GRM5ALDH1A1LMNASMN1; SMN2CHRNA1 | |
| SCHEMBL1755703 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11179394-B2 | Method for treating cancer using a combination of Chk1 and ATR inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11179394-B2 | Method for treating cancer using a combination of Chk1 and ATR inhibitors | CHEK1, CHEK2, ATR | GRM5 4189/4885ALDH1A1 2865/4885LMNA 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.